
MDAI Stock Forecast & Price Target
MDAI Analyst Ratings
Bulls say
Spectral AI is a company that utilizes artificial intelligence to provide predictive medical diagnostics. With its DeepView System, clinicians can make an informed decision regarding treatment options for wounds and burns, potentially improving efficiency and reducing costs. The company has seen growth in its R&D revenue and recently received significant funding from BARDA, indicating strong support for its technology. However, there are some risks, such as limited reimbursement and delays to regulatory processes, that could affect the company's growth potential. Overall, the company shows promise in its innovative approach and potential for recurring revenue through its licensing model, making it an attractive investment opportunity for investors with a long-term outlook.
Bears say
Spectral AI is facing potential downsides to their financial performance due to longer clinical and regulatory development timelines, potential setbacks in regulatory or commercial approvals, and lower uptake of their DeepView system in a commercial setting. Additionally, there is potential for upside to their financial performance if clinical and regulatory developments are faster, there are additional indications and market opportunities for their products, and they secure additional non-dilutive financing sources. However, there are currently limited OUS revenues and a change in CEO may not signal a change in strategy or timelines for the company's commercial focus.
This aggregate rating is based on analysts' research of Spectral AI Inc and is not a guaranteed prediction by Public.com or investment advice.
MDAI Analyst Forecast & Price Prediction
Start investing in MDAI
Order type
Buy in
Order amount
Est. shares
0 shares